文献速递中医内科中药与中成药合理使用中医康复

血塞通通过抑制ROCKII通路发挥卒中后长期神经保护作用

Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo.
PubMed 文献 · J Ethnopharmacol · 2021-02-20

该研究探讨血塞通(XST)是否通过抑制Nogo-A及ROCKII通路在永久性大脑中动脉闭塞(MCAO)大鼠及氧糖剥夺/复氧(OGD/R)SH-SY5Y细胞中发挥长期神经保护作用。结果显示XST减轻神经功能缺损和病理损伤、促进体重增加与突触再生、降低Nogo-A表达并抑制ROCKII通路,提示其可能通过抑制ROCKII通路辅助卒中恢复。

要点

  • 血塞通可减轻MCAO大鼠神经功能缺损并促进突触再生。
  • 血塞通降低Nogo-A表达并抑制ROCKII通路。
  • 体外SH-SY5Y细胞中血塞通抑制OGD/R诱导的Nogo-A及ROCKII激活。

核心结论

  • 血塞通可能通过抑制ROCKII通路发挥长期神经保护作用,辅助卒中恢复。

研究设计与样本

  • 研究采用永久性MCAO大鼠模型,分别给予血塞通、Y27632、血塞通联合Y27632及尼莫地平,观察14天和28天。
  • 体外建立SH-SY5Y细胞OGD/R模型,用CCK8法检测最佳OGD时间和血塞通浓度。
  • 采用TTC染色确认MCAO造模成功,NDS评估神经功能缺损,HE染色及IHC检测SYN和PSD-95评估缺血损伤与神经保护能力。
  • 通过IHC、Western blotting和qRT-PCR检测Nogo-A水平及ROCKII通路。

主要发现

  • 血塞通减轻MCAO大鼠神经功能障碍和病理损伤,促进体重增加和突触再生。
  • 血塞通降低MCAO大鼠Nogo-A mRNA和蛋白水平,并抑制ROCKII通路。
  • CCK8实验显示SH-SY5Y细胞最佳OGD时间为7 h,最佳血塞通浓度为20 μg/mL。
  • 血塞通明显抑制OGD/R诱导的SH-SY5Y细胞Nogo-A蛋白表达和ROCKII通路激活。

关键数值与推荐

  • SH-SY5Y细胞最佳OGD时间为7 h,最佳血塞通浓度为20 μg/mL。

临床怎么用

  • 血塞通可能作为卒中恢复期辅助治疗,通过抑制ROCKII通路发挥长期神经保护作用。
  • 临床可关注血塞通对神经功能缺损、突触再生及Nogo-A/ROCKII通路的调节作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Xuesaitong (XST) is a traditional Chinese medicine injection with neuroprotective properties and has been extensively used to treat stroke for many years. The main component of XST is Panax notoginseng saponins (PNS), which is the main extract of the Chinese herbal medicine Panax notoginseng. AIM OF THE STUDY: In this study, we investigated whether XST provided long-term neuroprotection by inhibiting neurite outgrowth inhibitor-A (Nogo-A) and the ROCKII pathway in experimental rats after middle cerebral artery occlusion (MCAO) and in SH-SY5Y cells exposed to oxygen-glucose deprivation/reperfusion (OGD/R). MATERIALS AND METHODS: Rats with permanent MCAO were administered XST, Y27632, XST plus Y27632, and nimodipine for 14 and 28 days. Successful MCAO onset was confirmed by 2,3,5-triphenyl tetrazolium chloride (TTC) staining. Neurological deficit score (NDS) was used to assess neurological impairment. Hematoxylin-eosin (HE) staining and immunohistochemical (IHC) analysis of synaptophysin (SYN) and postsynaptic density protein-95 (PSD-95) were performed to evaluate cerebral ischemic injury and the neuroprotective capability of XST. Nogo-A levels and the ROCKII pathway were detected by IHC analysis, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) to explore the protective mechanism of XST. OGD/R model was established in SH-SY5Y cells. Cell counting kit 8 (CCK8) was applied to detect the optimum OGD time and XST concentration. The expression levels Nogo-A and ROCKII pathway were determined using western blotting. RESULTS: Our results showed that XST reduced neurological dysfunction and pathological damage, promoted weight gain and synaptic regeneration, reduced Nogo-A mRNA and protein levels, and inhibited the ROCKII pathway in MCAO rats. CCK8 assay displayed that the optimal OGD time and optimal XST concentration were 7 h and 20 μg/mL respectively in SH-SY5Y cells. XST could evidently inhibit OGD/R-induced Nogo-A protein expression and ROCKII pathway activation in SH-SY5Y cells. CONCLUSIONS: The present study suggested that XST exerted long-term neuroprotective effects that assisted in stroke recovery, possibly through inhibition of the ROCKII pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou D, Cen K, Liu W, et al. Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo. J Ethnopharmacol. 2021. PMID: 33617967. doi:10.1016/j.jep.2021.113943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。